Back to Search
Start Over
Impact of the STAT1 N-terminal domain for fibrosarcoma cell responses to ɣ-irradiation
- Source :
- Experimental Results. 1
- Publication Year :
- 2020
- Publisher :
- Cambridge University Press (CUP), 2020.
-
Abstract
- Type I/II interferons (IFNα,β/IFNɣ) are cytokines that activate signal-transducer-and-activator-of-transcription-1 (STAT1). The STAT1 N-terminal domain (NTD) mediates dimerization and cooperative DNA-binding. The STAT1 DNA-binding domain (DBD) confers sequence-specific DNA-recognition. STAT1 has been connected to growth inhibition, replication stress and DNA-damage. We investigated how STAT1 and NTD/DBD mutants thereof affect fibrosarcoma cells. STAT1 and indicated mutants do not affect proliferation of resting and IFNα-treated cells as well as checkpoint kinase signaling, and phosphorylation of the tumor-suppressive transcription factor p53 ensuing ɣ-irradiation. Of the STAT1 reconstituted U3A cells those with STAT1 NTD mutants accumulate the highest levels of the replication stress/DNA-damage marker S139-phosphorylated histone H2AX (ɣH2AX). This is similarly seen with a STAT1 NTD/DBD double mutant, indicating transcription-independent effects. Furthermore, U3A cells with STAT1 NTD mutants are most susceptible to apoptotic DNA fragmentation and cleavage of the DNA repair protein PARP1. These data provide novel insights into the relevance of the STAT1 NTD.
- Subjects :
- 0301 basic medicine
congenital, hereditary, and neonatal diseases and abnormalities
biology
Chemistry
DNA damage
Cell
Mutant
Apoptotic DNA fragmentation
Cell biology
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
medicine.anatomical_structure
PARP1
030220 oncology & carcinogenesis
medicine
biology.protein
Phosphorylation
STAT1
Transcription factor
Subjects
Details
- ISSN :
- 2516712X
- Volume :
- 1
- Database :
- OpenAIRE
- Journal :
- Experimental Results
- Accession number :
- edsair.doi...........5941be3d0850893c75906bb34068ce7e
- Full Text :
- https://doi.org/10.1017/exp.2020.25